Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 136470-78-5 | Product Number: A2694
Abacavir
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$128.00
|
7 | 1 | 37 |
|
| 5G |
$435.00
|
1 | Contact Us | 16 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | A2694 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__4H__1__8N__6O = 286.34 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 136470-78-5 |
| Reaxys Registry Number | 7493116 |
| PubChem Substance ID | 253661597 |
| Merck Index (14) | 1 |
| MDL Number | MFCD00903850 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation [a]20/D | -53.0 to -57.0 deg(C=0.15, MeOH) |
Properties (reference)
| Melting Point | 161 °C(dec.) |
| Specific Rotation | -54° (C=0.15,MeOH) |
| Solubility in water | Insoluble |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P285 : In case of inadequate ventilation wear respiratory protection. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P272 : Contaminated work clothing must not be allowed out of the workplace. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P304 + P341 : IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. P302 + P352 : IF ON SKIN: Wash with plenty of soap and water. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. P363 : Wash contaminated clothing before reuse. P405 : Store locked up. |
Related Laws:
| RTECS# | GY5979200 |
Transport Information:
| HS Number | 2933.99.7500 |
Application
Abacavir: A Nucleoside Analog Reverse Transcriptase Inhibitor (RTI)
Abacavir is a nucleoside analog reverse transcriptase inhibitor (RTI) that inhibits HIV-1 in vitro with a potency similar to that of zidovudine [A2052]. Resistance to abacavir develops relatively slowly. Cross-resistance between abacavir and other RTIs, namely didanosine [D3066], zalcitabine [D3581] or lamivudine [L0217], but not zidovudine or stavudine [D3580], has been reported in vitro. HLA-B*5701 genetic screening have been reported to prevent drug hypersensitivity reactions caused by abacavir.
References
- Abacavir (a review)
- The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS (a review)
- HLA-B*5701 screening prior to abacavir prescription: Clinical and laboratory aspects (a review)
- Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.